Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma

Summary RAN, ZHX2 and RCBTB2 (CHC1L) expression was evaluated by quantitative real time reverse transcription polymerase chain reaction in plasma cells from 85 monoclonal gammopathies: 58 symptomatic multiple myeloma (MM) (52 untreated, six relapsed), eight smouldering MM, five monoclonal gammopathy of undetermined significance, four plasma cell leukaemias and 10 myeloid cell lines. ZHX2 was weakly expressed in high-risk/ proliferative disease compared to low-risk or indolent disease. High ZHX2 expression was associated with better response and longer survival after highdose therapy. RCBTB2 expression was weaker in hyperdiploid versus nonhyperdiploid cases while RAN was more expressed in symptomatic MM and cell lines.